Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Medtronic
Johnson and Johnson
Harvard Business School
Merck

Last Updated: May 19, 2022

TALICIA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Talicia, and what generic alternatives are available?

Talicia is a drug marketed by Redhill and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-nine patent family members in twenty-four countries.

The generic ingredient in TALICIA is amoxicillin; omeprazole magnesium; rifabutin. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; omeprazole magnesium; rifabutin profile page.

DrugPatentWatch® Generic Entry Outlook for Talicia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 12, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for TALICIA
International Patents:29
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for TALICIA
What excipients (inactive ingredients) are in TALICIA?TALICIA excipients list
DailyMed Link:TALICIA at DailyMed
Drug patent expirations by year for TALICIA
Drug Prices for TALICIA

See drug prices for TALICIA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for TALICIA
Generic Entry Date for TALICIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TALICIA

TALICIA is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TALICIA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TALICIA

Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Rifabutin-based compositions and methods for treating Helicobacter pylori infection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS

Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS

Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS

Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TALICIA

When does loss-of-exclusivity occur for TALICIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 14216373
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2015019264
Estimated Expiration: See Plans and Pricing

Canada

Patent: 00763
Estimated Expiration: See Plans and Pricing

Chile

Patent: 15002253
Estimated Expiration: See Plans and Pricing

China

Patent: 5163743
Estimated Expiration: See Plans and Pricing

Patent: 9893516
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0191559
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 56149
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 56149
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 17645
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 52411
Estimated Expiration: See Plans and Pricing

Israel

Patent: 0387
Estimated Expiration: See Plans and Pricing

Japan

Patent: 94529
Estimated Expiration: See Plans and Pricing

Patent: 16508516
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 8536
Estimated Expiration: See Plans and Pricing

Patent: 15010490
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 1754
Estimated Expiration: See Plans and Pricing

Philippines

Patent: 015501783
Estimated Expiration: See Plans and Pricing

Poland

Patent: 56149
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 56149
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 71400
Estimated Expiration: See Plans and Pricing

Patent: 15138708
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 201506318Q
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 56149
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2062357
Estimated Expiration: See Plans and Pricing

Patent: 150118176
Estimated Expiration: See Plans and Pricing

Spain

Patent: 44406
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 0249
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TALICIA around the world.

Country Patent Number Title Estimated Expiration
Croatia P20191559 See Plans and Pricing
Mexico 2015010490 COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE HELICOBACTER PYLORI. (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI.) See Plans and Pricing
Brazil 112015019264 composições farmacêuticas para o tratamento de helicobacter pylori See Plans and Pricing
South Korea 20150118176 헬리코박터 파일로리 치료용 약제학적 조성물 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI) See Plans and Pricing
Russian Federation 2671400 ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ОТ HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Moodys
Baxter
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.